QUOTED. 12 April 2020. Mike Dale.
Executive Summary
Abbott has received two CE marks, expanding access to the company’s TriClip minimally invasive tricuspid valve repair technology and its market-leading Xience everolimus-eluting coronary stent. Mike Dale, senior vice president of Abbott’s structural heart business, explained the significance of the news.
“Tricuspid regurgitation is considered the most undertreated valve issue. Our novel TriClip therapy offers the best possible outcomes for people suffering from a debilitating condition and gives doctors even more options for customizing repair of this complex anatomy." – Mike Dale, senior vice president, structural heart, Abbott
Click here for a free trial of Medtech Insight